Who Owns Eckert & Ziegler Strahlen- und Medizintechnik Company?

Eckert & Ziegler Strahlen- und Medizintechnik Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Eckert & Ziegler?

Understanding the ownership structure of a company is paramount for investors and stakeholders alike. The evolution of a company's ownership can reveal critical insights into its strategic direction, financial health, and long-term prospects. This is especially true for a dynamic Eckert & Ziegler Strahlen- und Medizintechnik SWOT Analysis, a leading medical technology company.

This article explores the fascinating Eckert & Ziegler ownership landscape, from its founding by Jürgen Ziegler and Andreas Eckert in 1997 to its current status as a publicly traded entity. Discover who owns Eckert & Ziegler, the major stakeholders, and how changes in ownership have shaped this Strahlen- und Medizintechnik company's journey. We will delve into the key players and their influence on this important player in the medical technology field.

The story of Eckert & Ziegler Strahlen- und Medizintechnik begins in the former German Democratic Republic. The company's roots trace back to a research institute, setting the stage for its future in the medical and industrial sectors. Following German reunification, the company evolved into what it is today.

In 1992, Jürgen Ziegler and Andreas Eckert co-founded BEBIG Isotopentechnik und Umweltdiagnostik GmbH. This marked the beginning of the Eckert & Ziegler Group. They acquired premises and patents from the research institute, which enabled them to produce radioactive sources for various applications.

The establishment of Eckert & Ziegler Strahlen- und Medizintechnik AG in Berlin in 1997 was a pivotal moment. This new entity served as a holding company, overseeing several specialized subsidiaries. These subsidiaries were involved in radioisotope processing and the development, manufacturing, and distribution of isotope components and medical devices.

Founders

Jürgen Ziegler and Andreas Eckert co-founded BEBIG Isotopentechnik und Umweltdiagnostik GmbH in 1992. This company was the precursor to the current Eckert & Ziegler Group. They played a key role in acquiring the necessary assets to begin production.

Early Ownership

Andreas Eckert is identified as a founder and major shareholder. While specific equity splits at the company's inception are not readily available in public records, he continues to hold a significant position. Early backers likely included angel investors or friends and family.

Company Structure

The founding of Eckert & Ziegler Strahlen- und Medizintechnik AG in 1997 established a holding company structure. This structure facilitated the management of various subsidiaries. These subsidiaries focused on processing radioisotopes and producing related products.

Initial Investments

Details on early investments, such as vesting schedules or buy-sell clauses, are not publicly disclosed. The initial funding likely came from a mix of sources. This included angel investors and possibly friends and family.

Vision and Specialization

The founding team's vision was to specialize in isotope technology. This was reflected in the establishment of the holding company and its subsidiaries. Their focus was on medical and industrial applications.

Public Information

Public records do not readily provide specific equity splits from the company's inception. Information on the early financial arrangements is limited. This makes it difficult to ascertain the exact ownership structure at the beginning.

The evolution of Eckert & Ziegler, from its origins to its current structure, highlights the strategic vision of its founders. The company's focus on isotope technology for medical and industrial uses has been a consistent theme throughout its history. For more details on the company's journey, consider reading a Brief History of Eckert & Ziegler Strahlen- und Medizintechnik.

Key Takeaways

The founders, Jürgen Ziegler and Andreas Eckert, played a pivotal role in establishing the company. Andreas Eckert remains a major shareholder. The company's early structure involved a holding company and specialized subsidiaries.

• The company's focus on isotope technology was evident from the start.
• Early investments likely included angel investors and family.
• Specific equity splits and financial details from the beginning are not publicly available.
• The company's history reflects a strategic vision in the medical technology company sector.

Eckert & Ziegler Strahlen- und Medizintechnik SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of ownership at Eckert & Ziegler Strahlen- und Medizintechnik AG, now Eckert & Ziegler SE, reflects strategic shifts and adaptations since its initial public offering in 1999. The company's ownership structure has been significantly influenced by several key events, including acquisitions, mergers, and spin-offs, each designed to optimize its operational efficiency and focus on core competencies. Understanding the current ownership landscape is crucial for investors and stakeholders interested in the medical technology company.

As of May 2025, the ownership structure of Eckert & Ziegler SE is composed of several key stakeholders. The founder, Andreas Eckert, remains a significant shareholder, holding 31.13% of the equities, which is valued at approximately €462 million. Institutional investors like JPMorgan Asset Management (UK) Ltd. and Norges Bank Investment Management also hold substantial shares, with 3.013% and 2.873% respectively. The public float accounts for 52.01%, representing shares available for public trading. These details provide insights into who owns Eckert & Ziegler and the distribution of its shares.

These strategic moves have reshaped the company's direction and governance, allowing for a more focused approach on core competencies and optimization of the corporate structure. These changes have had a significant impact on the company's strategy and governance. For more information on how the company approaches its market, you can read about the Marketing Strategy of Eckert & Ziegler Strahlen- und Medizintechnik.

Ownership Insights

Eckert & Ziegler's ownership structure is a blend of founder ownership, institutional investment, and public float.

• Andreas Eckert remains a key individual shareholder.
• Institutional investors hold significant portions of the shares.
• The public float provides liquidity for trading.
• Strategic events have shaped the ownership landscape.

Eckert & Ziegler Strahlen- und Medizintechnik PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The governance structure of Eckert & Ziegler Strahlen- und Medizintechnik SE is dualistic, featuring both an Executive Board and a Supervisory Board. The Executive Board manages the company's day-to-day operations, while the Supervisory Board oversees the Executive Board and is involved in significant decisions. As of January 2025, the Executive Board is composed of Dr. Harald Hasselmann, who serves as Chairman and CEO, Dr. Gunnar Mann, and Frank Yeager. This structure is designed to ensure effective management and oversight of the medical technology company.

The Supervisory Board is headed by Dr. Andreas Eckert, the founder and a major shareholder. Jutta Ludwig, formerly an Executive Board member, transitioned to the Supervisory Board on January 1, 2025. This transition highlights the company's commitment to experienced leadership and strategic oversight. The roles and responsibilities of each board are clearly defined to maintain a balance of power and ensure accountability within the company's operations, contributing to the overall Eckert & Ziegler owner structure.

Eckert & Ziegler's voting structure generally follows a one-share-one-vote principle. However, historical instances, such as the acquisition of IBt, highlight the existence of 'Beneficiary Shares'. These shares convey voting rights but not dividend rights, leading to potential discrepancies between ownership percentages and voting power in certain situations. Despite Dr. Andreas Eckert's significant stake, there is no recent public data indicating outsized control through special voting rights, suggesting a relatively stable governance environment regarding who owns Eckert & Ziegler.

Eckert & Ziegler's Governance

The company operates with a dualistic management system, ensuring both operational efficiency and robust oversight. The Executive Board manages daily operations, while the Supervisory Board monitors and advises. This structure helps maintain a balance of power and accountability.

• Dualistic Management: Executive and Supervisory Boards.
• Key Executives: Dr. Harald Hasselmann, Dr. Gunnar Mann, and Frank Yeager.
• Supervisory Board: Chaired by founder Dr. Andreas Eckert.
• Voting Structure: Primarily one-share-one-vote, with some exceptions.

Eckert & Ziegler Strahlen- und Medizintechnik Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, several developments have shaped the ownership landscape of Eckert & Ziegler. A key change in March 2024 was the conversion of Eckert & Ziegler Strahlen- und Medizintechnik AG into a Societas Europaea (SE), now operating as Eckert & Ziegler SE. This transition, however, did not impact the number of shares or the holdings of existing shareholders. The company's strategic direction has also been marked by significant moves, particularly the spin-off of its radiopharmaceuticals business.

A notable recent trend is the spin-off of the radiopharmaceuticals business, bundled into Pentixapharm AG, to Pentixapharm Holding AG. This transaction, announced in 2024, entitles shareholders of Eckert & Ziegler SE to receive one share of Pentixapharm Holding AG for each share held in Eckert & Ziegler SE. This strategic move aims to focus Eckert & Ziegler on its core competencies and potentially unlock value for shareholders by creating a separate entity for the radiopharmaceuticals segment.

In terms of leadership, Dr. Gunnar Mann joined the Executive Board on January 1, 2025, taking operational responsibility for the Medical segment. Jutta Ludwig transitioned from the Executive Board to the Supervisory Board on the same date. The company's strategic moves and leadership changes reflect its focus on specialized segments within the medical technology sector. For additional context, you can explore the Competitors Landscape of Eckert & Ziegler Strahlen- und Medizintechnik.

Ownership Structure Evolution

Eckert & Ziegler has undergone changes including a shift to an SE structure and the spin-off of its radiopharmaceuticals business. These moves aim to streamline operations.

Strategic Leadership Changes

Dr. Gunnar Mann's appointment in January 2025 and Jutta Ludwig's transition highlight adjustments in the management team. These changes reflect a focus on specific market opportunities.

Financial Outlook

The company has proposed a dividend of €0.50 per share for 2024, approved in April 2025. Analysts generally hold a 'Moderate Buy' rating.

Market Sentiment

Analyst consensus leans towards a 'Moderate Buy' for Eckert & Ziegler, with an average price target of €67.55, indicating positive expectations.

Eckert & Ziegler Strahlen- und Medizintechnik Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs